JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

JNJ

190.31

-0.15%↓

ABT

127.15

+0.3%↑

MDT

94.09

+0.34%↑

VEEV

295.48

+0.77%↑

A

146.74

-0.99%↓

Search

PerkinElmer Inc

Fermé

SecteurSoins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

14M

55M

Ventes

56M

720M

P/E

Moyenne du Secteur

41.439

37.461

BPA

1.18

Rendement du dividende

0.3

Marge bénéficiaire

7.667

Employés

11,000

EBITDA

22M

194M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+11.23% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.30%

2.33%

Date du Prochain Dividende

7 nov. 2025

Date du Prochain Détachement de Dividende

16 janv. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

370M

11B

Ouverture précédente

0

Clôture précédente

0

Sentiment de l'Actualité

By Acuity

32%

68%

84 / 373 Classement par Healthcare

PerkinElmer Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

27 oct. 2025, 23:32 UTC

Acquisitions, Fusions, Rachats

CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline

27 oct. 2025, 23:00 UTC

Acquisitions, Fusions, Rachats

Australia's AUB Opens Books to EQT After Receiving $3.44 Billion Takeover Offer

27 oct. 2025, 21:42 UTC

Résultats

Waste Management 3Q Revenue Climbs, Sees Fiscal Year Revenue at Low End of Prior View

27 oct. 2025, 23:43 UTC

Market Talk

Nikkei May Rise on Easing U.S.-China Trade Tensions -- Market Talk

27 oct. 2025, 23:42 UTC

Market Talk

Gold Rises on Likely Technical Recovery -- Market Talk

27 oct. 2025, 23:37 UTC

Market Talk

Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

27 oct. 2025, 23:00 UTC

Résultats

The Good Vibes Are Back on Wall Street -- WSJ

27 oct. 2025, 22:45 UTC

Acquisitions, Fusions, Rachats

Australia's AUB Opens Books to EQT After Receiving $3.44B Takeover Offer

27 oct. 2025, 22:06 UTC

Market Talk
Résultats

Nucor Expects Weaker Steel Market in 4Q -- Market Talk

27 oct. 2025, 22:05 UTC

Résultats

China Southern Airlines: Continued Improvements in Business Environment Supported Results >1055.HK

27 oct. 2025, 22:04 UTC

Résultats

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct. 2025, 22:04 UTC

Résultats

China Southern Airlines 3Q Net CNY3.84B, Up 20.3% on Year >1055.HK

27 oct. 2025, 22:03 UTC

Résultats

China Southern Airlines 3Q Rev CNY51.37B, Up 3.0% on Year >1055.HK

27 oct. 2025, 21:27 UTC

Résultats

Waste Management 3Q Rev Climbs, Sees FY Rev at Low End of Prior View

27 oct. 2025, 21:19 UTC

Résultats

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 oct. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

27 oct. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

27 oct. 2025, 20:37 UTC

Résultats

Waste Management: Decrease From Prior Rev Expectations Is Primarily Related to Further Decline in Recycled Commodity Pricing, Modestly Lower Rev Expectations From Healthcare Solutions >WM

27 oct. 2025, 20:37 UTC

Résultats

Waste Management: 2025 Free Cash Flow Guidance Remains Between $2.8B and $2.9B >WM

27 oct. 2025, 20:37 UTC

Résultats

Waste Management: 2025 Total Co Rev Is Now Expected Approximately $25.275B >WM

27 oct. 2025, 20:37 UTC

Résultats

Waste Management: Affirming 2025 Adjusted Operating EBITDA Guidance Between $7.475B and $7.625B >WM

27 oct. 2025, 20:31 UTC

Résultats

Nucor Sees 4Q Earnings Lower Than 3Q

27 oct. 2025, 20:30 UTC

Résultats

Nucor 3Q Steel Mills Total Shipments 6.43M Tons >NUE

27 oct. 2025, 20:30 UTC

Résultats

Nucor 3Q EPS $2.63 >NUE

27 oct. 2025, 20:30 UTC

Résultats

Nucor 3Q Net $607M >NUE

27 oct. 2025, 20:30 UTC

Résultats

Nucor 3Q Sales $8.52B >NUE

27 oct. 2025, 20:30 UTC

Résultats

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

27 oct. 2025, 20:30 UTC

Résultats

Waste Management 3Q Adj EPS $1.98 >WM

27 oct. 2025, 20:30 UTC

Résultats

Waste Management 3Q Rev $6.44B >WM

27 oct. 2025, 20:30 UTC

Résultats

Waste Management 3Q Net $603M >WM

Comparaison

Variation de prix

PerkinElmer Inc prévision

Objectif de Prix

By TipRanks

11.23% hausse

Prévisions sur 12 Mois

Moyen 110 USD  11.23%

Haut 126 USD

Bas 99 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

14 ratings

8

Achat

6

Maintien

0

Vente

Sentiment

By Acuity

84 / 373Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat